Home > Tina Vilsbøll, EASD 2020 – Oral GLP-1RA therapy and individualized care
Diabetes
Watch Time: 5:13 mins

Tina Vilsbøll, EASD 2020 – Oral GLP-1RA therapy and individualized care

Published Online: October 7th 2020

We were delighted to speak with Prof. Tina Vilsbøll (University of Copenhagen, Copenhagen, Denmark) about the approval of semaglutide and the impact on the GLP-1RA landscape, and the movement towards individualizing care in patients with type 2 diabetes.

Questions

  1. What has been the impact of the approval of oral semaglutide in the GLP-1RA landscape? (0:15)
  2. How have recent advances impacted on the opportunity for individualised diabetes care? (1:19)
  3. What factors should be considered in tailoring oral GLP-1RA therapy to the individual? (2:29)
  4. How do you see the role of oral GLP-1RAs evolving in the future? (3:42)

 

Disclosures: Prof. Tina Vilsbøll reports financial disclosures with the following: Amgen, AZ, BMS, Boehringer, Gielad, Lilly, Novo, Sanofi, Sunpharma.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.

Share this Video
Related Videos In Diabetes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar